Zsolt Sárszegi

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Deepak L. Bhatt, Philippe Gabríel Steg, Shamir R Mehta et al. · The Lancet · 2019 · 210 citations · Full text

Medicine, Cardiology, Pharmacotherapy +15

Antioxidant and Anti-Inflammatory Effects in RAW264.7 Macrophages of Malvidin, a Major Red Wine Polyphenol

Eszter Bognár, Zsolt Sárszegi, Alíz Szabó et al. · PLoS ONE · 2013 · 152 citations · Full text

Life Sciences, Biochemistry, Immunology +17

BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases

Zsolt Sárszegi, Eszter Bognár, Balázs Gaszner et al. · Molecular and Cellular Biochemistry · 2012 · 54 citations

Life Sciences, Cell Biology, Pharmacology +11

A novel SOD-mimetic permeability transition inhibitor agent protects ischemic heart by inhibiting both apoptotic and necrotic cell death

Zita Bognár, Tamás Kálai, Anita Pálfi et al. · Free Radical Biology and Medicine · 2006 · 45 citations

Medicine, Cardiology, Pharmacology +11

Comparison of Aortic and Carotid Arterial Stiffness Parameters in Patients With Verified Coronary Artery Disease

Balázs Gaszner, Zsófia Lenkey, Miklós Illyés et al. · Clinical Cardiology · 2011 · 40 citations · Full text

Medicine, Cardiology, Clinical Cardiology +14